In this video from Clinical Trials at the Summit, Carl D. Regillo, MD, FACS, discusses the use of tyrosine kinase inhibitors for wet age-related macular degeneration and diabetic retinopathy with ...

Selected tyrosine kinase inhibitors, known or believed to be in development in cancer treatment trials, are summarized as are some of the key issues that must be addressed if these compounds are ...

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs ...

Panelist discusses how Bruton tyrosine kinase inhibitors fit into real-world practice with community physicians often using monotherapy, while emphasizing the importance of specialist knowledge to ...

Panelist discusses how efficacy and safety data from trials like ELEVATE-TN and CLL14 inform treatment decisions, noting that while both regimens are effective, patients with 17p deletion tend to ...

The Emirates Drug Establishment (EDE) has granted official approval for Rilzabrutinib, the first oral Bruton’s tyrosine ...

Sino-American biopharma Ascentage Pharma announced that its proprietary novel Bcl-2 selective inhibitor lisaftoclax (APG-2575 ...

Targeting SHP2 has emerged as a promising approach for treating cancers driven by receptor tyrosine kinases. Although allosteric SHP2 inhibitors have shown strong antitumor activity in preclinical ...

A research team led by Prof. Liu Qingsong from the Hefei Institutes of Physical Science of the Chinese Academy of Science has ...

The FDA granted accelerated approval to the tyrosine kinase inhibitor sunvozertinib (Zegfrovy) for advanced non-small cell ...

Thailand has taken a major step in its healthcare journey as the Chulabhorn Royal Academy (CRA) launches Imcranib 100 for ...

"Imcranib 100", the first targeted cancer drug in tablet form developed and produced in Thailand, is the result of the ...